Ir-Med, Inc. (IRME) — SEC Filings
Ir-Med, Inc. (IRME) — 34 SEC filings. Latest: 8-K (Dec 12, 2025). Includes 22 8-K, 5 10-Q, 2 S-1/A.
View Ir-Med, Inc. on SEC EDGAR
Overview
Ir-Med, Inc. (IRME) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 12, 2025: IR-Med, Inc. announced on December 7, 2025, a change in its principal executive offices to ZHR Industrial Zone Rosh Pina, Israel. The company, formerly known as International Display Advertising, Inc. until January 5, 2021, also reported on director departures, elections, officer appointments, and c
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 1 bearish, 32 neutral, 1 mixed. The dominant filing sentiment for Ir-Med, Inc. is neutral.
Filing Type Overview
Ir-Med, Inc. (IRME) has filed 22 8-K, 5 10-Q, 2 S-1/A, 2 S-1, 2 10-K, 1 10-K/A with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of IRME's 34 recent filings, 1 were flagged as high-risk, 20 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$1,474 thousand |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $63 thousand |
| Operating Margin | N/A |
| Total Assets | $175 thousand |
| Total Debt | $800 thousand |
Key Executives
- Ran Ziskind
- Yaniv Cohen
- Oded Bashan
- Oded Har-Even, Esq.
- Dr. Yaron Paz
- Mr. Shimon Mizrahi
- Mr. Aviad Mizrahi
- Yossi Gross
Industry Context
The medical device industry is highly competitive and capital-intensive, requiring significant R&D investment and regulatory approvals. Companies like IR-Med often rely on external financing to fund product development and commercialization. The market for pressure-related medical devices is growing, driven by an aging population and increased awareness of preventative care, but faces challenges from established players and rapid technological advancements.
Top Tags
corporate-governance (7) · filing (6) · material-agreement (5) · equity-sale (5) · management-change (5) · 10-Q (4) · 8-K (3) · SEC Filing (3) · ipo (3) · executive-changes (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 000-56492 | Identifies the company's filing with the SEC. |
| IRS Employer Identification Number | 84-4516398 | Company's tax identification number. |
| Loss for the six-months period ended June 30, 2025 | $1,474 thousand | Increased from $1,023 thousand in the prior year |
| Cash and cash equivalents as of June 30, 2025 | $63 thousand | Decreased from $129 thousand at December 31, 2024 |
| Net cash used in operating activities for six months ended June 30, 2025 | $(181) thousand | Indicates negative operational cash flow |
| Accumulated deficit as of June 30, 2025 | $18,212 thousand | Increased from $16,738 thousand at December 31, 2024 |
| Total Stockholders' deficit as of June 30, 2025 | $(625) thousand | Worsened from $(294) thousand at December 31, 2024 |
| Financial expenses, net for six months ended June 30, 2025 | $935 thousand | Significantly increased from $7 thousand in the prior year |
| Unpaid amount from Williamsburg Venture Holdings, LLC | $500,000 | Investor failed to remit payment for put shares |
| Shares of common stock outstanding as of August 14, 2025 | 77,238,961 | Increased from 71,008,144 shares at December 31, 2024 |
| Aggregate amount of convertible promissory notes issued | $31,200 | Issued to Mr. Ran Ziskind, Mr. Yaniv Cohen, and Mr. Oded Bashan |
| Annual interest rate on convertible loans and short-term loan | 9% | Cost of recent financing |
| Registration Statement Number | 333-287229 | Identifies the specific S-1 filing being amended by IR-Med, Inc. |
| SIC Code | 3845 | Primary Standard Industrial Classification for Electromedical & Electrotherapeutic Apparatus, indicating IR-Med's industry. |
| Filing Date | 2025-05-22 | The date IR-Med, Inc. submitted the S-1/A amendment to the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ir-Med, Inc. (IRME)?
Ir-Med, Inc. has 34 recent SEC filings from Feb 2024 to Dec 2025, including 22 8-K, 5 10-Q, 2 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IRME filings?
Across 34 filings, the sentiment breakdown is: 1 bearish, 32 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Ir-Med, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ir-Med, Inc. (IRME) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ir-Med, Inc.?
Key financial highlights from Ir-Med, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IRME?
The investment thesis for IRME includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ir-Med, Inc.?
Key executives identified across Ir-Med, Inc.'s filings include Ran Ziskind, Yaniv Cohen, Oded Bashan, Oded Har-Even, Esq., Dr. Yaron Paz and 3 others.
What are the main risk factors for Ir-Med, Inc. stock?
Of IRME's 34 assessed filings, 1 were flagged high-risk, 20 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Ir-Med, Inc.?
Forward guidance and predictions for Ir-Med, Inc. are extracted from SEC filings as they are enriched.